Differential regulation of bladder cancer growth by various glucocorticoids: Corticosterone and prednisone inhibit cell invasion without promoting cell proliferation or reducing cisplatin cytotoxicity

Cancer Chemotherapy and Pharmacology

Volumn 74, Issue 2, 2014, Pages 249-255

  Ishiguro, Hitoshi ^a,b   Kawahara, Takashi ^a,b   Zheng, Yichun ^a,b,c   Kashiwagi, Eiji ^a   Li, Yi ^b,c   Miyamoto, Hiroshi ^a,b,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Bladder cancer; Chemotherapy; Cisplatin; Comedication; Glucocorticoids

Indexed keywords

BETAMETHASONE; BUDESONIDE; CISPLATIN; CORTICOSTERONE; DEXAMETHASONE; FLUDROCORTISONE ACETATE; FLUMETASONE; FLUTICASONE PROPIONATE; GELATINASE B; HYDROCORTISONE; INTERLEUKIN 6; PREDNISONE; TRIAMCINOLONE; VASCULOTROPIN;

APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER GROWTH; CELL GROWTH; CELL INVASION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR INVASION;

ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL MOVEMENT; CELL PROLIFERATION; CISPLATIN; CORTICOSTERONE; DEXAMETHASONE; FLOW CYTOMETRY; GLUCOCORTICOIDS; HUMANS; INTERLEUKIN-6; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; PREDNISONE; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84907599003     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2496-7     Document Type: Article

References (21)

1. Miyamoto H, Miller JS, Fajardo DA, Lee TK, Netto GJ, Epstein JI (2010) Non-invasive papillary urothelial neoplasms: the 2004 WHO/ISUP classification system. Pathol Int 60:1-8
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69-90
3. Netto GJ (2012) Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet? Nat Rev Urol 9:41-51
4. Nicolaides NC, Galata Z, Kino T, Chrousos GP, Charmandari E (2010) The human glucocorticoid receptor: molecular basis of biologic function. Steroids 75:1-12
5. Basch E, Prestrud A, Hesketh PJ et al (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29:4189-4198
6. Schlossmacher G, Stevens A, White A (2011) Glucocorticoid receptor-mediated apoptosis: mechanisms of resistance in cancer cells. J Endocrinol 211:17-25
7. Ishiguro H, Kawahara T, Li Y, Miyamoto H (2013) Anti-tumor activities of dexamethasone. In: Sauvage A, Levy M (eds) Dexamethasone: therapeutic uses, mechanism of action and potential side effects. Nova Science Publishers, New York, pp 117-135
8. Zheng Y, Izumi K, Li Y, Ishiguro H, Miyamoto H (2012) Contrary regulation of bladder cancer cell proliferation and invasion by dexamethasone-mediated glucocorticoid receptor signals. Mol Cancer Ther 11:2621-2632
9. Ishiguro H, Kawahara T, Zheng Y, Netto GJ, Miyamoto H (2014) Reduced glucocorticoid receptor expression predicts bladder tumor recurrence and progression. Am J Clin Pathol (in press)
10. Zhang C, Mattern J, Haferkamp A et al (2006) Corticosteroidinduced chemotherapy resistance in urological cancers. Cancer Biol Ther 5:59-64 (Pubitemid 43234979)
11. Zhang C, Wenger T, Mattern J et al (2007) Clinical and mechanistic aspects of glucocorticoid-induced chemotherapy resistance in the majority of solid tumors. Cancer Biol Ther 6:278-287 (Pubitemid 46641636)
12. Reyes-Moreno C, Frenette G, Boulanger J, Lavergne E, Govindan MV, Koutsilieris M (1995) Mediation of glucocorticoid receptor function by transforming growth factor beta 1 expression in human PC-3 prostate cancer cells. Prostate 26:260-269
13. Nishimura K, Nonomura N, Satoh E et al (2001) Potential mechanism for the effects of dexamethasone on growth of androgenindependent prostate cancer. J Natl Cancer Inst 93:1739-1746 (Pubitemid 33130263)
14. Yano A, Fujii Y, Iwai A, Kageyama Y, Kihara K (2006) Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells. Clin Cancer Res 12:3003-3009 (Pubitemid 43837344)
15. Domingo-Domenech J, Oliva C, Rovira A et al (2006) Interleukin 6, a nuclear factor-κB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-κB inhibition by PS-1145 enhances docetaxel antitumor activity. Clin Cancer Res 12:5578-5586 (Pubitemid 44497276)
16. Yemelyanov A, Czwornog J, Chebotaev D et al (2007) Tumor suppressor activity of glucocorticoid receptor in the prostate. Oncogene 26:1885-1896 (Pubitemid 46474637)
17. Gao Q-Z, Lu J-J, Liu Z-D, Zhang H, Wang S-M, Xu H (2008) Dexamethasone suppresses DU145 cell proliferation and cell cycle through inhibition of the extracellular signal-related kinase 1/2 pathway and cyclin D1 expression. Asian J Androl 10:635-641 (Pubitemid 351865769)
18. Wilson C, Scullin P, Worthington J et al (2008) Dexamethasone potentiates the antiangiogenic activity of docetaxel in castrationresistant prostate cancer. Br J Cancer 99:2054-2064
19. Meikle AW, Tyler FH (1977) Potency and duration of action of glucocorticoids. Effects of hydrocortisone, prednisone and dexamethasone on human pituitary-adrenal function. Am J Med 63:200-207 (Pubitemid 8160340)
20. Leung DYM, Hanifin JM, Charlesworth EN et al (1997) Disease management of atopic dermatitis: a practice parameter. Ann Allergy Asthma Immunol 79:197-211 (Pubitemid 27499972)
21. Singer M, Webb AR (2005) Oxford handbook of critical care, 2nd edn. Oxford University Press, New York